News | May 12, 2008

Laser Ablation System Assists Removal of 975 Cardiac Leads

May 13, 2008 – Spectranetics’ excimer laser sheath safely and effectively assists removal of pacing and defibrillator leads, according to the study, “Large, Single-catheter, Single-operator Experience with Transvenous Lead Extraction: Outcomes and Changing Indications,” featured in the April issue of HeartRhythm.

The study represents a seven year retrospective analysis of data from 498 lead extraction procedures involving 975 leads. The conclusion demonstrates safe extraction of leads successfully removed with laser assistance.

The Spectranetics Laser Sheath (SLS II) use cool ultraviolet light to ablate scar tissue that holds problematic leads in place. A circle of fibers that emit pulses of energy travel over the cardiac lead towards the tip to dissolve scar tissue that binds the lead to the body. Once the scar tissue is dissolved, the lead can be safely removed. Spectranetics’ Lead Locking Device (LLD) technology can also be used to assist removal by creating secure traction during procedures that may or may not require laser assistance.

The retrospective study at Brigham and Women’s Hospital in Boston was designed to examine indications, outcomes and complications associated with transvenous lead extraction. Dr. Laurence Epstein, Chief of Cardiac Arrhythmia Services at Brigham and Women’s Hospital acted as the single-operator in the study handling all 498 lead extraction procedures throughout the seven year period. The study showed a success rate of over 97 percent with only two major complications, and no deaths. These two major complications out of 498 procedures resulted in a major complication rate of only 0.4 percent. The published article also highlights concerns surrounding existing formal recommendations for lead removal given the technologies available to assist the process. The article notes that “the rate of complications from abandoned leads reported in one study was as low as 5.5 percent, which still is higher than the complication rate from extraction.”

“We were interested in reviewing our outcomes, at a high volume center with an experienced operator,” said Dr. Epstein. “Historically the indications for lead extraction have been tempered by the risks, real and perceived, associated with the procedure. This study demonstrates that transvenous lead extraction can be performed safely and effectively in a wider population of patients.” Dr. Epstein further describes his strategy, explaining, “Hopefully, this will reduce the number of patients subjected to open heart procedures and the risks and complications of abandoned leads. However, this is not an endorsement for the performance of extraction, more widely, in inexperienced hands. Excellent results are achieved through careful preparation, planning and experience.”

For more information: www.spectranetics.com

Related Content

Biosense Webster Announces Initial Results From First-in-Human QDOT-FAST Study
News | Ablation Systems | May 16, 2019
Johnson & Johnson Medical Devices Companies announced that Biosense Webster, Inc.’s QDot Micro catheter...
CardioFocus Announces Results From HeartLight X3 Ablation System Pivotal Study
News | Ablation Systems | May 16, 2019
CardioFocus Inc. announced the presentation of results from its pivotal confirmatory study evaluating the HeartLight X3...
New Global Consensus Statement Addresses Catheter Ablation of Ventricular Arrhythmias
News | Ablation Systems | May 14, 2019
The Heart Rhythm Society (HRS) in partnership with three other professional societies issued an international consensus...
Netherlands Hospital to Install State-of-the-Art MRI Ablation Center
News | Ablation Systems | May 13, 2019
Imricor announced the signing of a commercial agreement with the Haga Hospital in The Hague, Netherlands to outfit a...
A CyberHeart cardiac ablation radiotherapy treatment plan showing where the radiation beam will ablate for a noninvasive pulmonary vein isolation procedure. Varian acquires, buys, purchases Cyberheart.

A CyberHeart cardiac ablation radiotherapy treatment plan showing where the radiation beams will ablate for a noninvasive pulmonary vein isolation procedure to treat an arrhythmia.

Feature | Ablation Systems | May 10, 2019 | Dave Fornell, Editor
May 10, 2019 — Radiation oncology vendor Varian announced it acquired the start-up company CyberHeart, which has deve
Ablation Reduces Risk of Dementia in Patients With AFib and Carotid Artery Disease
News | Ablation Systems | May 08, 2019
Even though many medical practitioners may opt not to perform procedures on higher-risk patients, new research finds it...
CardioFocus Announces European CE Mark Approval Of HeartLight X3 System
News | Ablation Systems | April 16, 2019
CardioFocus Inc. announced the European CE Mark approval of the HeartLight X3 Endoscopic Ablation System.
First Patient Treated With QDot Micro Ablation Catheter
News | Ablation Systems | February 04, 2019
Biosense Webster has enrolled and treated the first patient in its U.S. Investigational Device Exemption (IDE) study...
FDA Approves TactiCath Contact Force Ablation Catheter, Sensor Enabled
Technology | Ablation Systems | January 21, 2019
Abbott announced U.S. Food and Drug Administration (FDA) approval of the TactiCath Contact Force Ablation Catheter,...
First Patient Treated in STELLAR Atrial Fibrillation IDE Study
News | Ablation Systems | November 30, 2018
Johnson & Johnson Medical Devices Companies announced that Biosense Webster Inc. has enrolled and treated the first...
Overlay Init